HPC Offered for PRESERVE Expansion
Summary
Ossium recognizes that not all patients who could benefit from Ossium's HPC, Marrow can access the PRESERVE trial for logistical or eligibility reasons. The HOPE program is expanded access program to serve these patients by providing our bone marrow product
Arms & interventions
- OtherBone Marrow Transplant with Ossium's HPC, Marrow (bone marrow recovered from deceased organ and tissue donors)
The HOPE Program does not include any investigational drugs. The medicines and procedures in this program are standard of care for a transplant. Bone marrow cells from a deceased organ and tissue donor for use in your transplant is the only product offered to you by Ossium Health.
Outcome measures
Primary
Neutrophil engraftment
1\. To determine cumulative incidences of neutrophil engraftment (ANC ≥500/µL for 3 consecutive values)
Time frame: 28 days
Eligibility criteria
Study locations (4)
University of Alabama, Birmingham
Birmingham, Alabama, 35294
Henry Ford Health
Detroit, Michigan, 48202
The Ohio State University Medical Center
Columbus, Ohio, 43210
Tristar Centennial Medical Center
Nashville, Tennessee, 37203